Preference for distinct functional conformations of the dopamine transporter alters the relationship between subjective effects of cocaine and stimulation of mesolimbic dopamine

Biological Psychiatry

Volumn 76, Issue 10, 2014, Pages 802-809

  Kohut, Stephen J ^a   Hiranita, Takato ^a   Hong, Soo Kyung ^a,b   Ebbs, Aaron L ^a   Tronci, Valeria ^a   Green, Jennifer ^a   Garcés Ramírez, Linda ^a,c   Chun, Lauren E ^a   Mereu, Maddalena ^a   Newman, Amy H ^a   Katz, Jonathan L ^a   Tanda, Gianluigi ^a  

^a NATIONAL INSTITUTE ON DRUG ABUSE   (United States)

^b Korea Advanced Institute of Science and Technology (KAIST)   (South Korea)

^c INSTITUTO POLITÉCNICO NACIONAL   (Mexico)

Author keywords

ADHD; Benztropine analogs; Cocaine discrimination; Dopamine microdialysis; Drug abuse and addiction; Nucleus accumbens shell

Indexed keywords

BENZATROPINE; COCAINE; DOPAMINE; DOPAMINE TRANSPORTER; METHYLPHENIDATE; DOPAMINE UPTAKE INHIBITOR;

ANIMAL EXPERIMENT; ARTICLE; ATTENTION DEFICIT DISORDER; CONTROLLED STUDY; DISCRIMINATIVE STIMULUS; DRUG ABUSE; HYPOTHESIS; MALE; MICRODIALYSIS; NONHUMAN; NUCLEUS ACCUMBENS; PRIORITY JOURNAL; PROTEIN CONFORMATION; RAT; ANIMAL; DRUG EFFECTS; DRUG SELF ADMINISTRATION; INSTRUMENTAL CONDITIONING; METABOLISM; PHYSIOLOGY; SPRAGUE DAWLEY RAT;

ANIMALS; COCAINE; CONDITIONING, OPERANT; DOPAMINE; DOPAMINE PLASMA MEMBRANE TRANSPORT PROTEINS; DOPAMINE UPTAKE INHIBITORS; MALE; MICRODIALYSIS; NUCLEUS ACCUMBENS; PROTEIN CONFORMATION; RATS; RATS, SPRAGUE-DAWLEY; SELF ADMINISTRATION;

EID: 84927913557     PISSN: 00063223     EISSN: 18732402     Source Type: Journal    
DOI: 10.1016/j.biopsych.2014.03.031     Document Type: Article

References (60)

1. Haertzen CA, Hickey JE (1987): Addiction Research Center Inventory (ARCI): Measurement of euphoria and other drug effects. In: Bozarth MA, editor. Methods of Assessing the Reinforcing Properties of Abused Drugs. New York: Springer-Verlag
2. Holtzman SG (1985): Drug discrimination studies. Drug Alcohol Depend 14:263-282
3. Schuster CR, Johanson CE (1988): Relationship between the discriminative stimulus properties and subjective effects of drugs. Psychopharmacol Ser 4:161-175
4. Callahan PM, De La Garza R 2nd, Cunningham KA (1997): Mediation of the discriminative stimulus properties of cocaine by mesocorticolimbic dopamine systems. Pharmacol Biochem Behav 57:601-607
5. Dworkin SI, Smith JE (1988): Neurobehavioral pharmacology of cocaine. NIDA Res Monogr 88:185-198
6. Wise RA (2005): Forebrain substrates of reward and motivation. J Comp Neurol 493:115-121
7. Czoty PW, Makriyannis A, Bergman J (2004): Methamphetamine discrimination and in vivo microdialysis in squirrel monkeys. Psychopharmacology (Berl) 175:170-178
8. Desai RI, Paronis CA, Martin J, Desai R, Bergman J (2010): Monoaminergic psychomotor stimulants: Discriminative stimulus effects and dopamine efflux. J Pharmacol Exp Ther 333:834-843
9. Volkow ND, Wang GJ, Fischman MW, Foltin RW, Fowler JS, Abumrad NN, et al. (1997): Relationship between subjective effects of cocaine and dopamine transporter occupancy. Nature 386:827-830
10. Bergman J, Madras BK, Johnson SE, Spealman RD (1989): Effects of cocaine and related drugs in nonhuman primates. III. Selfadministration by squirrel monkeys. J Pharmacol Exp Ther 251: 150-155
11. Katz JL, Izenwasser S, Terry P (2000): Relationships among dopamine transporter affinities and cocaine-like discriminative-stimulus effects. Psychopharmacology (Berl) 148:90-98
12. Kuhar MJ, Ritz MC, Boja JW (1991): The dopamine hypothesis of the reinforcing properties of cocaine. Trends Neurosci 14:299-302
13. Loland CJ, Desai RI, Zou MF, Cao J, Grundt P, Gerstbrein K, et al. (2008): Relationship between conformational changes in the dopamine transporter and cocaine-like subjective effects of uptake inhibitors. Mol Pharmacol 73:813-823
14. Newman AH, Katz JL (2009): Atypical dopamine uptake inhibitors that provide clues about cocaine's mechanism at the dopamine transporter. Top Med Chem 4:95-129
15. Runyon SP, Carroll FI (2008): Tropane-based dopamine transporteruptake inhibitors. In: Trudell ML, Izenwasser S, editors. Dopamine Transporters, Chemistry, Biology, and Pharmacology. Hoboken, NJ: John Wiley & Sons, 125-170
16. Tanda G, Newman A, Katz JL (2009): Discovery of drugs to treat cocaine dependence: Behavioral and neurochemical effects of atypical dopamine transport inhibitors. In: Enna SJ, Williams M, editors. Advances in Pharmacology, Contemporary Drug Discovery. San Diego: Academic Press, 253-289
17. Schmitt KC, Rothman RB, Reith ME (2013): Nonclassical pharmacology of the dopamine transporter: Atypical inhibitors, allosteric modulators, and partial substrates. J Pharmacol Exp Ther 346:2-10
18. Desai RI, Kopajtic TA, French D, Newman AH, Katz JL (2005): Relationship between in vivo occupancy at the dopamine transporter and behavioral effects of cocaine, GBR 12909 [1-{2-[bis-(4-fluorophenyl) methoxy]ethyl}-4-(3-phenylpropyl)piperazine], and benztropine analogs. J Pharmacol Exp Ther 315:397-404
19. Punja S, Zorzela L, Hartling L, Urichuk L, Vohra S (2013): Long-acting versus short-acting methylphenidate for paediatric ADHD: A systematic review and meta-analysis of comparative efficacy. BMJ Open 3:e002312
20. Beuming T, Kniazeff J, Bergmann ML, Shi L, Gracia L, Raniszewska K, et al. (2008): The binding sites for cocaine and dopamine in the dopamine transporter overlap. Nat Neurosci 11:780-789
21. Schmitt KC, Reith ME (2011): The atypical stimulant and nootropic modafinil interacts with the dopamine transporter in a different manner than classical cocaine-like inhibitors. PLoS One 6:e25790
22. Agoston GE, Wu JH, Izenwasser S, George C, Katz J, Kline RH, Newman AH (1997): Novel N-substituted 3 alpha-[bis(4'-fluorophenyl)methoxy] tropane analogues: Selective ligands for the dopamine transporter. J Med Chem 40:4329-4339
23. Newman AH, Kline RH, Allen AC, Izenwasser S, George C, Katz JL (1995): Novel 4'-substituted and 4',4"-disubstituted 3 alpha-(diphenylmethoxy) tropane analogs as potent and selective dopamine uptake inhibitors. J Med Chem 38:3933-3940
24. Berridge CW, Devilbiss DM, Spencer RC, Schmeichel BE, Arnsten FT (2012): Attention deficit hyperactivity disorder. In: Barrett JE, Coyle JT, Williams M, editors. Translational Neuroscience. New York: Cambridge University Press, 303-320
25. Schmeichel BE, Zemlan FP, Berridge CW (2013): A selective dopamine reuptake inhibitor improves prefrontal cortex-dependent cognitive function: Potential relevance to attention deficit hyperactivity disorder. Neuropharmacology 64:321-328
26. Tanda G, Pontieri FE, Di Chiara G (1997): Cannabinoid and heroin activation of mesolimbic dopamine transmission by a common mu1 opioid receptor mechanism. Science 276:2048-2050
27. Tanda G, Pontieri FE, Frau R, Di Chiara G (1997): Contribution of blockade of the noradrenaline carrier to the increase of extracellular dopamine in the rat prefrontal cortex by amphetamine and cocaine. Eur J Neurosci 9:2077-2085
28. Zahm DS (1999): Functional-anatomical implications of the nucleus accumbens core and shell subterritories. Ann N Y Acad Sci. 877:113-128
29. Pontieri FE, Tanda G, Di Chiara G (1995): Intravenous cocaine, morphine, and amphetamine preferentially increase extracellular dopamine in the"shell" as compared with the"core" of the rat nucleus accumbens. Proc Natl Acad Sci U S A 92:12304-12308
30. Paxinos G, Watson C (1998): The Rat Brain in Stereotaxic Coordinates, 4th ed. San Diego: Academic Press
31. Garces-Ramirez L, Green JL, Hiranita T, Kopajtic TA, Mereu M, Thomas A, et al. (2011): Sigma receptor agonists: Receptor binding and effects on mesolimbic dopamine neurotransmission assessed by microdialysis. Biol Psychiatry 69:208-217
32. Tanda G, Ebbs A, Newman AH, Katz JL (2005): Effects of 4'-chloro-3 alpha-(diphenylmethoxy)-tropane on mesostriatal, mesocortical, and mesolimbic dopamine transmission: Comparison with effects of cocaine. J Pharmacol Exp Ther 313:613-620
33. Tanda G, Ebbs AL, Kopajtic TA, Elias LM, Campbell BL, Newman AH, Katz JL (2007): Effects of muscarinic M1 receptor blockade on cocaineinduced elevations of brain dopamine levels and locomotor behavior in rats. J Pharmacol Exp Ther 321:334-344
34. Snedecor GW, Cochran WG (1967): Statistical Methods. 6th ed. Ames, IA: Iowa State University Press
35. Baker LE, Riddle EE, Saunders RB, Appel JB (1993): The role of monoamine uptake in the discriminative stimulus effects of cocaine and related compounds. Behav Pharmacol 4:69-79
36. Broadbent J, Michael EK, Riddle EE, Apple JB (1991): Involvement of dopamine uptake in the discriminative stimulus effects of cocaine. Behav Pharmacol 2:187-197
37. Tanda G, Li SM, Mereu M, Thomas AM, Ebbs AL, Chun LE, et al. (2013): Relations between stimulation of mesolimbic dopamine and place conditioning in rats produced by cocaine or drugs that are tolerant to dopamine transporter conformational change. Psychopharmacology (Berl) 229:307-321
38. Kollins SH (2007): Abuse liability of medications used to treat attention-deficit/hyperactivity disorder (ADHD). Am J Addict 16(suppl 1): 35-42; quiz 43-44
39. Wilens TE, Adler LA, Adams J, Sgambati S, Rotrosen J, Sawtelle R, et al. (2008): Misuse and diversion of stimulants prescribed for ADHD: A systematic review of the literature. J Am Acad Child Adolesc Psychiatry 47:21-31
40. Ferragud A, Velazquez-Sanchez C, Hernandez-Rabaza V, Nacher A, Merino V, Carda M, et al. (2009): A dopamine transport inhibitor with markedly low abuse liability suppresses cocaine self-administration in the rat. Psychopharmacology (Berl) 207:281-289
41. Hiranita T, Soto PL, Newman AH, Katz JL (2009): Assessment of reinforcing effects of benztropine analogs and their effects on cocaine self-administration in rats: Comparisons with monoamine uptake inhibitors. J Pharmacol Exp Ther 329:677-686
42. Li SM, Kopajtic TA, O'Callaghan MJ, Agoston GE, Cao J, Newman AH, et al. (2011): N-substituted benztropine analogs: Selective dopamine transporter ligands with a fast onset of action and minimal cocainelike behavioral effects. J Pharmacol Exp Ther 336:575-585
43. Hiranita T, Kohut SJ, Soto PL, Tanda G, Kopajtic TA, Katz JL (2014): Preclinical efficacy of N-substituted benztropine analogs as antagonists of methamphetamine self-administration in rats. J Pharmacol Exp Ther 348:174-191
44. Velazquez-Sanchez C, Ferragud A, Murga J, Carda M, Canales JJ (2010): The high affinity dopamine uptake inhibitor, JHW 007, blocks cocaineinduced reward, locomotor stimulation and sensitization. Eur Neuropsychopharmacol 20:501-508
45. Velazquez-Sanchez C, Ferragud A, Renau-Piqueras J, Canales JJ (2010): Therapeutic-like properties of a dopamine uptake inhibitor in animal models of amphetamine addiction. Int J Neuropsychopharmacol 14: 655-665
46. Chen N, Zhen J, Reith ME (2004): Mutation of Trp84 and Asp313 of the dopamine transporter reveals similar mode of binding interaction for GBR12909 and benztropine as opposed to cocaine. J Neurochem 89: 853-864
47. Kopajtic TA, Liu Y, Surratt CK, Donovan DM, Newman AH, Katz JL (2010): Dopamine transporter-dependent and -independent striatal binding of the benztropine analog JHW 007, a cocaine antagonist with low abuse liability. J Pharmacol Exp Ther 335:703-714
48. Reith ME, Berfield JL, Wang LC, Ferrer JV, Javitch JA (2001): The uptake inhibitors cocaine and benztropine differentially alter the conformation of the human dopamine transporter. J Biol Chem 276:29012-29018
49. Campbell VC, Kopajtic TA, Newman AH, Katz JL (2005): Assessment of the influence of histaminergic actions on cocaine-like effects of 3alpha-diphenylmethoxytropane analogs. J Pharmacol Exp Ther 315: 631-640
50. Tanda G, Kopajtic TA, Katz JL (2008): Cocaine-like neurochemical effects of antihistaminic medications. J Neurochem 106:147-157
51. Katz JL, Kopajtic TA, Agoston GE, Newman AH (2004): Effects of N-substituted analogs of benztropine: Diminished cocaine-like effects in dopamine transporter ligands. J Pharmacol Exp Ther 309:650-660
52. Hiranita T, Soto PL, Kohut SJ, Kopajtic T, Cao J, Newman AH, et al. (2011): Decreases in cocaine self-administration with dual inhibition of the dopamine transporter and sigma receptors. J Pharmacol Exp Ther 339:662-677
53. Carroll FI, Howell LL, Kuhar MJ (1999): Pharmacotherapies for treatment of cocaine abuse: Preclinical aspects. J Med Chem 42:2721-2736
54. Hiranita T, Wilkinson DS, Hong WC, Zou MF, Kopajtic TA, Soto PL, et al. (2014): 2-Isoxazol-3-phenyltropane derivatives of cocaine: molecular and atypical system effects at the dopamine transporter. J Pharmacol Exp Ther 349:297-309. doi:10.1124/jpet.113.212738
55. Desai RI, Kopajtic TA, Koffarnus M, Newman AH, Katz JL (2005): Identification of a dopamine transporter ligand that blocks the stimulant effects of cocaine. J Neurosci 25:1889-1893
56. Raje S, Cao J, Newman AH, Gao H, Eddington ND (2003): Evaluation of the blood-brain barrier transport, population pharmacokinetics, and brain distribution of benztropine analogs and cocaine using in vitro and in vivo techniques. J Pharmacol Exp Ther 307:801-808
57. Raje S, Cornish J, Newman AH, Cao J, Katz JL, Eddington ND (2005): Pharmacodynamic assessment of the benztropine analogues AHN- 1055 and AHN-2005 using intracerebral microdialysis to evaluate brain dopamine levels and pharmacokinetic/pharmacodynamic modeling. Pharm Res 22:603-612
58. Tanda G, Newman A, Ebbs AL, Tronci V, Green J, Tallarida RJ, Katz JL (2009): Combinations of cocaine with other dopamine uptake inhibitors: Assessment of additivity. J Pharmacol Exp Ther 330:802-809
59. Katz NS, Guiard BP, El Mansari M, Blier P (2010): Effects of acute and sustained administration of the catecholamine reuptake inhibitor nomifensine on the firing activity of monoaminergic neurons. J Psychopharmacol 24:1223-1235
60. Newman AH, Kulkarni S (2002): Probes for the dopamine transporter: New leads toward a cocaine-abuse therapeutic-A focus on analogues of benztropine and rimcazole. Med Res Rev 22:429-464.